Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.

IF 2.4 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiorenal Medicine Pub Date : 2024-01-01 Epub Date: 2024-03-27 DOI:10.1159/000538347

Pingjiang Li, Yuying Cui, Xiaoming Xu, Jianjun Dong, Lin Liao

{"title":"Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.","authors":"Pingjiang Li, Yuying Cui, Xiaoming Xu, Jianjun Dong, Lin Liao","doi":"10.1159/000538347","DOIUrl":null,"url":null,"abstract":"Background: The mineralocorticoid receptor plays an important pathophysiological role in cardiorenal diseases by causing inflammation and fibrosis. Mineralocorticoid receptor antagonists (MRAs) are well known in treating cardiovascular disease and diverse nephropathies. However, the first-generation MRA (spironolactone) and the second-generation MRA (eplerenone) remain underutilized because of the risk of inducing severe adverse events. As a selective nonsteroidal MRA, finerenone is safer and more effective and improves cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, the effect of finerenone on cardiorenal outcomes in patients of different races and kidney function (estimated glomerular filtration rate) is unclear.Summary: In this review, we summarized the impact of finerenone on patients with CKD and T2DM from randomized controlled trials. The synthesis of published data aims to address the questions pertaining to the cardiorenal benefits of finerenone among various racial groups and different levels of kidney function.Key message: Finerenone presents racial differences and effects associated with kidney function in CKD and T2DM patients. Due to the limited data for subgroups, it is prudent to approach the conclusion with caution.","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"227-234"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538347","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The mineralocorticoid receptor plays an important pathophysiological role in cardiorenal diseases by causing inflammation and fibrosis. Mineralocorticoid receptor antagonists (MRAs) are well known in treating cardiovascular disease and diverse nephropathies. However, the first-generation MRA (spironolactone) and the second-generation MRA (eplerenone) remain underutilized because of the risk of inducing severe adverse events. As a selective nonsteroidal MRA, finerenone is safer and more effective and improves cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, the effect of finerenone on cardiorenal outcomes in patients of different races and kidney function (estimated glomerular filtration rate) is unclear.

Summary: In this review, we summarized the impact of finerenone on patients with CKD and T2DM from randomized controlled trials. The synthesis of published data aims to address the questions pertaining to the cardiorenal benefits of finerenone among various racial groups and different levels of kidney function.

Key message: Finerenone presents racial differences and effects associated with kidney function in CKD and T2DM patients. Due to the limited data for subgroups, it is prudent to approach the conclusion with caution.

查看原文本刊更多论文

非格列酮对不同种族心肾功能的益处以及慢性肾病患者的肾功能。

背景：矿物质皮质激素受体在心肾疾病中扮演着重要的病理生理角色，可导致炎症和纤维化。矿物皮质激素受体拮抗剂（MRA）在治疗心血管疾病和各种肾病方面广为人知。然而，第一代 MRA（螺内酯）和第二代 MRA（依普利酮）由于存在诱发严重不良反应的风险，仍未得到充分利用。作为一种选择性非甾体类 MRA，非格列酮（fineerenone）更安全、更有效，可改善慢性肾脏病（CKD）和 2 型糖尿病（T2DM）患者的心肾功能。然而，对于不同种族和肾功能（估计肾小球滤过率 [eGFR]）的患者，非格列酮对心肾功能预后的影响尚不明确。摘要：在本综述中，我们总结了随机对照试验（RCT）中非格列酮对 CKD 和 T2DM 患者的影响。对已发表数据的综述旨在解决与非格列酮对不同种族群体和不同肾功能水平的心肾功能益处有关的问题：非格列酮会造成种族差异，并对 CKD 和 T2DM 患者的肾功能产生影响。由于亚组数据有限，得出结论需谨慎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiorenal Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-UROLOGY & NEPHROLOGY

CiteScore

5.40

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.